Search alternatives:
significant non » significant amount (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 3,272 for search '(( significant non decrease ) OR ( significant gap decrease ))', query time: 0.53s Refine Results
  1. 1
    Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019).

    Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  3. 3
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 4
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year.

    Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Anthropometric characteristics of smokers and non-smokers.

    Anthropometric characteristics of smokers and non-smokers. by Prasanna Herath (20714794)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Detailed treatment status of people who received non- pharmacological treatment at first diagnosis.

    Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Respiratory clinical characteristics of smokers and non-smokers.

    Respiratory clinical characteristics of smokers and non-smokers. by Prasanna Herath (20714794)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Lung function parameters between smokers and non-smokers.

    Lung function parameters between smokers and non-smokers. by Prasanna Herath (20714794)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later.

    Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    The table shows the significant and non-significant altered group with different parameters.

    The table shows the significant and non-significant altered group with different parameters. by Ashraf Attia Mahmoud (21262201)

    Published 2025
    Save to List
    Saved in:
  17. 17
    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia disorder.

    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    General information of patient who diagnosis insomnia disorder (N = 518,119).

    General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Treatment at first diagnosis of insomnia disorder (%).

    Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Significantly Enriched Pathways.

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: